EFFECT OF UPADACITINIB ON INTENSITY OF SCORAD ITEMS AND IMPACTS TO ITCH AND SLEEP: ANALYSIS FROM THE MEASURE UP 1 AND MEASURE UP 2 STUDIES

被引：0
|
作者：
Cameron, Michael [1 ]
Magnolo, Nina [2 ]
Prajapati, Vimal H. [3 ]
Haque, Adel [4 ]
Lee, Wan-Ju [5 ]
Altman, Katherine [5 ]
Platt, Andrew M. [5 ]
Lane, Michael C. [5 ]
Calimlim, Brian M. [5 ]
Taieb, Alain [6 ]
机构：
[1] Mt Sinai Hosp, Dept Dermatol, New York, NY USA
[2] Univ Hosp Munster, Dept Dermatol, Munster, Germany
[3] Univ Calgary, Div Dermatol, Dept Med, Calgary, AB, Canada
[4] Jefferson Hlth Northeast, Dept Med, Jefferson, AR USA
[5] AbbVie Inc, N Chicago, IL USA
[6] Univ Bordeaux, INSERM 1312, Bordeaux, France
来源：
ACTA DERMATO-VENEREOLOGICA | 2023年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P10.18
引用
收藏
页码：56 / 57
页数：2
相关论文
共 50 条
  • [31] Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
    Jonathan I. Silverberg
    Melinda J. Gooderham
    Amy S. Paller
    Mette Deleuran
    Christopher G. Bunick
    Linda F. Stein Gold
    DirkJan Hijnen
    Brian M. Calimlim
    Wan-Ju Lee
    Henrique D. Teixeira
    Xiaofei Hu
    Shiyu Zhang
    Yang Yang
    Ayman Grada
    Andrew M. Platt
    Diamant Thaçi
    American Journal of Clinical Dermatology, 2024, 25 : 485 - 496
  • [32] Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
    Silverberg, Jonathan I.
    Gooderham, Melinda J.
    Paller, Amy S.
    Deleuran, Mette
    Bunick, Christopher G.
    Gold, Linda F. Stein
    Hijnen, Dirkjan
    Calimlim, Brian M.
    Lee, Wan-Ju
    Teixeira, Henrique D.
    Hu, Xiaofei
    Zhang, Shiyu
    Yang, Yang
    Grada, Ayman
    Platt, Andrew M.
    Thaci, Diamant
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2024, 25 (03) : 485 - 496
  • [33] Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double- blind, randomised controlled phase 3 trials
    Guttman-Yassky, Emma
    Teixeira, Henrique D.
    Simpson, Eric L.
    Papp, Kim A.
    Pangan, Aileen L.
    Blauvelt, Andrew
    Thaci, Diamant
    Chu, Chia-Yu
    Hong, H. Chih-Ho
    Katoh, Norito
    Paller, Amy S.
    Calimlim, Brian
    Gu, Yihua
    Hu, Xiaofei
    Liu, Meng
    Yang, Yang
    Liu, John
    Tenorio, Allan R.
    Chu, Alvina D.
    Irvine, Alan D.
    LANCET, 2021, 397 (10290): : 2151 - 2168
  • [34] Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
    Simpson, Eric L.
    Prajapati, Vimal H.
    Leshem, Yael A.
    Chovatiya, Raj
    de Bruin-Weller, Marjolein S.
    Staender, Sonja
    Pink, Andrew E.
    Calimlim, Brian M.
    Lee, Wan-Ju
    Teixeira, Henrique
    Ladizinski, Barry
    Hu, Xiaofei
    Yang, Yang
    Liu, Yingyi
    Liu, Meng
    Grada, Ayman
    Platt, Andrew M.
    Silverberg, Jonathan I.
    DERMATOLOGY AND THERAPY, 2024, 14 (05) : 1127 - 1144
  • [35] Characterization of hematologic and transaminase laboratory findings associated with upadacitinib in moderate-to-severe atopic dermatitis: Results of two phase 3 trials (measure up 1 and 2)
    Silverberg, Jonathan I.
    Gooderham, Melinda J.
    de Bruin-Weller, Marjolein S.
    Papp, Kim A.
    Aoki, Valeria
    Paller, Amy S.
    Ofori, Sarah
    Tenorio, Allan R.
    Liu, Yingyi
    Liu, Jianzhong
    Chovatiya, Raj
    CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (08): : 1010 - 1010
  • [36] Characterization of haematological and transaminase laboratory findings associated with upadacitinib use in moderate-to-severe atopic dermatitis: results of two phase III Trials (Measure Up 1 and 2)
    Silverberg, J. I.
    Gooderham, M. J.
    de Bruin-Weller, M. S.
    Papp, K. A.
    Aoki, V.
    Paller, A. S.
    Ofori, S.
    Tenorio, A. R.
    Liu, Y.
    Liu, J.
    Chovatiya, Raj
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E168 - E169
  • [37] Efficacy of upadacitinib vs dupilumab for moderate-to-severe atopic dermatitis: analysis of time spent in itch response state from the Heads Up study
    Blauvelt, Andrew
    de Bruin-Weller, Marjolein
    Kwatra, Shawn G.
    Gooderham, Melinda J.
    Kim, Brian
    Liu, Yingyi
    Chu, Alvina D.
    Ofori, Sarah
    Platt, Andrew
    Calimlim, Brian M.
    Silverberg, Jonathan, I
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II28 - II29
  • [38] EFFICACY OF UPADACITINIB VS DUPILUMAB FOR MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS OF TIME SPENT IN ITCH RESPONSE STATE FROM THE HEADS UP STUDY
    Blauvelt, Andrew
    de Bruin-Weller, Marjolein S.
    Kwatra, Shawn G.
    Gooderham, Melinda J.
    Kim, Brian
    Liu, Yingyi
    Chu, Alvina
    Oforia, Sarah
    Platt, Andrew
    Calimlim, Brian
    Silverberg, Jonathan I.
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 21 - 21
  • [39] WHETHER TO MEASURE CHANGE FROM BASE-LINE OR ABSOLUTE LEVEL IN STUDIES OF CHILDRENS CARDIOVASCULAR REACTIVITY - A 2-YEAR FOLLOW-UP
    MURPHY, JK
    ALPERT, BS
    WALKER, SS
    JOURNAL OF BEHAVIORAL MEDICINE, 1991, 14 (04) : 409 - 419
  • [40] Consequences of ignoring the response-shift and measure non-invariant items in sleep studies: an empirical data based simulation of the treatment effect of CBT-I on dysfunctional sleep beliefs
    Chen, Po-Yi
    Yang, Chien-Ming
    SLEEP MEDICINE, 2020, 74 : 99 - 108
12345